MPAACS: Magnesium for the Prevention of Atrial Arrhythmias After Cardiac Surgery

• Status: Terminated
• Trial end date: 2009-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of our research is to determine whether treatment with magnesium will reduce the incidence of atrial fibrillation in patients undergoing cardiac surgery. Several small studies of magnesium have already been conducted, but these studies were small and the results conflicting. A large, well-conducted study of magnesium treatment is required to definitively determine whether magnesium is effective in preventing this common complication after surgery. In addition, our study will include patients undergoing valvular surgery, a group previously excluded from research despite the fact that they are at increased risk of atrial fibrillation.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of British Columbia
• Collaborator: Heart and Stroke Foundation of Canada

Criteria

Inclusion Criteria:

• patient undergoing coronary artery bypass surgery with or without valve procedure

• scheduled for on-pump or cardiopulmonary bypass protocol

Exclusion Criteria:

• existing atrial fibrillation/flutter in the past year or on antiarrhythmic medications

• ventricular fibrillation

• sustained ventricular tachycardia

• 2nd or 3rd degree heart block

• paroxysmal supraventricular tachycardia

• major aortic repair planned during open-heart procedure

• permanent atrial/ventricular pacemaker implanted

• dialysis dependent or creatinine clearance < 35 umoles/min or oliguric/anuric renal failure

• patient intolerant of beta blockers

• patient has reactive airways disease dependent on regular beta-adrenergic agents

• patient is scheduled to undergo off-pump surgical protocol